A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs

Nanda Kishore Routhu, Emory University
Narayanaiah Cheedarla, Emory University
Sailaja Gangadhara, Emory University
Venkata Satish Bollimpelli, Emory University
Arun K. Boddapati, Emory University
Ayalnesh Shiferaw, Emory University
Sheikh Rahman, Emory University
Anusmita Sahoo, Emory University
Venkata Edara, Emory University
Lilin Lai, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Immunity
Volume: Volume 54, Number 3
Publisher: Cell Press | 2021-03-09, Pages 542+-
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1016/j.immuni.2021.02.001
Permanent URL: https://pid.emory.edu/ark:/25593/vsdsv

Final published version: http://dx.doi.org/10.1016/j.immuni.2021.02.001

Copyright information:
© 2021 Elsevier Inc.
Accessed July 4, 2024 12:00 PM EDT
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs

Highlights

- Generated MVA-based COVID-19 vaccine encoding prefusion-stabilized spike (MVA/S)

- MVA/S vaccination induces strong nAb response and CD8⁺ T cell response in macaques

- MVA/S vaccine protects macaques from SARS-CoV-2 infection and lung immunopathology

- MVA/S vaccine prevents infection-induced inflammation and B cell abnormalities in lungs

In Brief

Modified vaccinia Ankara (MVA) vector-based vaccines are attractive because of their excellent safety and ability to induce long-lived humoral and cellular immunity in humans. Routhu et al. show that an MVA-based COVID-19 vaccine encoding prefusion-stabilized spike (MVA/S) induces strong neutralizing antibody and CD8⁺ T cell responses and protects macaques from SARS-CoV2 infection, immunopathology, and infection-induced B cell abnormalities in the lungs.
A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs

Nanda Kishore Routhu,1,2,11 Narayanaiah Cheedarla,1,2,11 Sailaja Gangadhara,1,2,11 Venkata Satish Bollimpelli,1,2,11 Arun K. Boddapati,1,3 Ayalnesh Shiferaw,1,3 Sheikh Abdul Rahman,1,2 Anusmita Sahoo,1,2 Venkata Viswanadh Edara,1,4 Lilin Lai,1,3 Katharine Foyd,1,4 Shelly Wang,1 Stephanie Fischinger,1 Caroline Atyeo,1 Sally A. Shin,1 Sanjeev Gumber,6 Shannon Kirejczyk,6 Joyce Cohen,1 Sherrie M. Jean,1 Jennifer S. Wood,7 Fawn Connor-Stroud,1 Rachelle L. Stammen,7 Amit A. Upadhyay,1 Kathryn Pellegrini,1 David Montefiori,1 Pei-Yong Shi,9 Vineet D. Menachery,10 Galit Alter,5 Thomas H. Vanderford,1 Steven E. Bosinger,14 Mehul S. Suthar,1,3 and Rama Rao Amara1,2,12,*

1Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA
2Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, GA 30322, USA
3Department of Pathology, Emory School of Medicine, Emory University, Atlanta, GA 30322, USA
4Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA
5Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
6Division of Pathology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA
7Division of Animal Resources, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA
8Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA
9Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, TX, USA
10Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, USA
11These authors contributed equally
12Lead contact
*Correspondence: ramara@emory.edu
https://doi.org/10.1016/j.immuni.2021.02.001

SUMMARY

A combination of vaccination approaches will likely be necessary to fully control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Here, we show that modified vaccinia Ankara (MVA) vectors expressing membrane-anchored pre-fusion stabilized spike (MVA/S) but not secreted S1 induced strong neutralizing antibody responses against SARS-CoV-2 in mice. In macaques, the MVA/S vaccination induced strong neutralizing antibodies and CD8+ T cell responses, and conferred protection from SARS-CoV-2 infection and virus replication in the lungs as early as day 2 following intranasal and intratracheal challenge. Single-cell RNA sequencing analysis of lung cells on day 4 after infection revealed that MVA/S vaccination also protected macaques from infection-induced inflammation and B cell abnormalities and lowered induction of interferon-stimulated genes. These results demonstrate that MVA/S vaccination induces neutralizing antibodies and CD8+ T cells in the blood and lungs and is a potential vaccine candidate for SARS-CoV-2.

INTRODUCTION

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a pandemic. As of January 21, 2021, SARS-CoV-2 has infected more than 95 million people, and over 2 million people have succumbed to coronavirus disease 2019 (COVID-19) disease. Thus, there is an urgent need for development of a vaccine that can rapidly induce immunity and prevent infection. Studies of closely related coronaviruses, such as SARS-associated coronavirus (SARS-CoV) and Middle East Respiratory Syndrome-related coronavirus (MERS-CoV), demonstrate that a strong neutralizing antibody response against the spike protein can effectively prevent infection (Chan et al., 2015; Haagmans et al., 2016; Xu et al., 2019; Yong et al., 2019). Building on these data, a number of vaccines are currently under development for SARS-CoV-2 using a variety of platforms, including mRNA, viral vectors, DNA, and proteins with different adjuvants (Brouwer et al., 2021; Corbett et al., 2020; Gao et al., 2020; Keech et al., 2020; Kramer, 2020; Laczkó et al., 2020; Mercado et al., 2020; Poland et al., 2020; Sahin et al., 2020; Smith et al., 2020; Tostanoski et al., 2020; van Doremalen et al., 2020; Walls et al., 2020; Yu et al., 2020). Phenomenal progress has already been made in a very short time. mRNA-based (Corbett et al., 2020; Laczkó et al., 2020; Sahin et al., 2020), adenoviral vector-based (Mercado et al., 2020; Tostanoski et al., 2020; van Doremalen et al., 2020), and spike trimer protein-based (Gao et al., 2020; Keech et al., 2020) vaccines are at the forefront and show induction of a strong...
neutralizing antibody response in macaques and humans. In addition, these vaccines confer protection from SARS-CoV-2 infection and replication in the lungs following intranasal and intratracheal challenge in macaques. Recent data from mRNA and chimpanzee adenovirus-based vaccines in human efficacy trials also show that these vaccines can protect humans from COVID-19 and have been approved for emergency use. Although remarkable progress has been made, many challenges still exist for SARS-CoV-2 vaccine development. These include lack of long-term safety and immunogenicity data for humans, poor induction of a CD8+ T cell response, lack of cross-reactive protective immunity against other human betacoronaviruses with pandemic potential, failure to provide protection against SARS-CoV-2 replication in the nasopharynx, and requirement of cold storage. A combination of vaccination approaches is needed to tackle these critical challenges. There is still a great need for development of SARS-CoV-2 vaccines using different platforms, especially ones that can synergize with current front runners to enhance the induction and durability of neutralizing antibodies and CD8 T cell responses with long-term safety.

Modified vaccinia Ankara (MVA) is a highly attenuated strain of vaccinia virus. The safety, immunogenicity, and protective capacity of replication-deficient MVA has been well established, and it is used widely to develop vaccines against infectious diseases and cancer in preclinical research and humans (Gilbert, 2013; Iyer and Amara, 2014). There are several advantages to MVA-based vaccines. (1) They are safe and well tolerated, including in HIV-infected individuals (Thompson et al., 2016). (2) They induce strong antibody responses after a single vaccination and can be boosted at least 10-fold with a second dose (Amara et al., 2002; Brault et al., 2017; Domi et al., 2018; Goepfert et al., 2011, 2014). (3) MVA vaccine-induced antibody responses in humans are durable, with little contraction over a 6-month time frame (Goepfert et al., 2014). (4) MVA can be delivered through multiple routes and can be used to generate a mucosal antibody response. (5) MVA can accommodate large inserts (>10 kb) that will allow expression of multiple antigens in a single vector. (6) MVA-vectored recombinants are stable and can be produced at high titer, facilitating vaccine manufacturing. (7) MVA vaccines can induce CD4 and CD8 T cell responses important for protection against some viral infections (Amara et al., 2002). (8) A lyophilized MVA vaccine can be stored at 37°C for 2 weeks and at 4°C for longer than a year (Zhang et al., 2007). (9) MVA-based vaccines have been shown to protect against SARS-CoV, MERS-CoV, Zika virus, and Ebola virus in animal models (Bisht et al., 2004; Brault et al., 2017; Domi et al., 2018; Haagmans et al., 2016). In addition, MVA-based vaccines can serve as excellent boosting agents for DNA-based and other viral vector-based vaccines, including chimpanzee adenovirus- and Ad26-based vaccines to boost cellular and humoral immunity (Amara et al., 2001; Barouch et al., 2012; Ewer et al., 2016).

In this study, we developed two MVA-based vaccines that express a membrane-anchored full-length spike protein (MVA/S) stabilized in a prefusion state or the soluble secreted trimeric S1 of the spike (MVA/S1). Both immunogens contained the receptor-binding domain (RBD), a known target of antibody-mediated neutralization in SARS-CoV-2-infected individuals (Suthar et al., 2020). MVA/S also incorporated two mutations that have been shown to maintain the spike protein in a prefusion confirmation (Pallesen et al., 2017; Wrapp et al., 2020). Using a mouse model, we selected the MVA/S vaccine based on its ability to induce a neutralizing antibody response. Vaccination of rhesus macaques followed by SARS-CoV-2 challenge demonstrated that the MVA/S vaccine induces neutralizing antibodies and CD8 T cells, protects from SARS-CoV-2 infection and replication in the lungs, and thus is a potential vaccine candidate for SARS-CoV-2.

RESULTS

MVA vaccines express full-length stabilized spike and trimeric soluble S1 proteins

To develop the MVA recombinants, we synthesized the full-length spike gene (amino acids 1–1,273) with stabilizing mutations (K986P and V987P) or the S1 region with a small portion of the S2 region (amino acids 14–780). To promote active secretion of S1, we replaced amino acids 1–14 of the spike sequence with the signal sequence from Granulocyte macrophage-colony stimulating factor (GM-CSF) (Figure 1A). Both sequences were optimized for MVA codon use, corrected for poxvirus transcription termination sequences, and cloned into the pLW73 vector, which allowed us to insert the recombinant sequences under the mH5 promoter into the essential region of MVA. The recombinants were selected as described previously (Chea et al., 2019) and characterized for protein expression by flow cytometry and western blotting. As expected, MVA/S expressed high amounts (based on mean fluorescence intensity) of spike on the cell surface (Figure 1B), and the expressed protein had a molecular mass of about 180 kDa (Figure 1C). Similarly, MVA/S1 was expressed intracellularly (Figure 1B), and a molecular mass of about 114 kDa was also secreted into the supernatants (Figure 1C). The spike protein expressed by MVA/S on the surface seemed to be folded correctly based on strong binding to ACE2 (Figure 1D). The S1 protein was found to form trimers based on the gel filtration profile and native PAGE analysis (Figure 1E).

MVA/S, but not MVA/S1, induces a strong neutralizing antibody response in mice

We immunized BALB/c mice with MVA/S or MVA/S1 at weeks 0 and 3 and measured binding antibody responses to total and different parts of spike (i.e., RBD, S1, and S) using ELISA 2 weeks after prime and boost (Figure 2). Although both vaccines induced a strong binding antibody response to S, they differentially targeted binding to RBD and S1 (Figure 2A; Figure S1A). The MVA/S sera showed higher binding to the RBD, whereas MVA/S1 sera showed higher binding to S1. This was interesting, considering that S1 protein includes the RBD region, and suggests that antibody binding in sera from MVA/S1-vaccinated mice may be targeting regions outside of the RBD. We further confirmed this differential targeting of antibody using a Luminex assay (Figure S1B). Analysis of immunoglobulin G (IgG) subclass and Fc-gamma receptor (FcγR) binding of an RBD-specific antibody showed strong IgG2a response and binding to all three FcγRIs tested, with the strongest binding to FcγR2 and FcγR4 in the MVA/S group (Figure 2B). In contrast, poor binding of the RBD-specific antibody was observed in general with MVA/S1 sera. However, the
S1-specific antibody showed similar results in both groups (Figure S2C). In addition, we also observed induction of spike-specific IgG responses in bronchoalveolar lavage (BAL) fluid (Figure 2C). Similar to serum, the RBD-specific IgG responses were higher in the MVA/S group compared with the MVA/S1 group. These results demonstrated differential targeting of a spike-specific antibody with a T helper 1 (Th1) profile induced by the MVA/S and MVA/S1 vaccines.

We next evaluated the neutralization capacity of serum collected 2 weeks after boost from MVA-vaccinated mice using mNeonGreen SARS-CoV-2 virus and defined 50% reduction in focus reduction neutralization titer (FRNT) (Figure 2D). We observed a strong neutralizing antibody response in sera from mice vaccinated with MVA/S that ranged from 20–900 with a median of 200 (Figure 2D; Figure S1D). In contrast, we did not observe any detectable neutralization activity in sera from mice immunized with MVA/S1. This was despite the fact that MVA/S1 mice showed a higher binding antibody response to S1 and S proteins. The neutralization titer correlated directly with the RBD binding titer and negatively with the S1 binding titer.
In particular, it correlated with the RBD-specific IgG2a binding titer (Figure S1E). These results demonstrate that MVA/S immunogen can induce a strong neutralizing antibody response against SARS-CoV-2 and could be a potential vaccine for SARS-CoV-2. Importantly, they also reveal that MVA/S1 is not a good vaccine because it failed to induce a neutralizing antibody response.

To further understand the failure of the MVA/S1 vaccine to induce strong RBD binding antibodies and neutralizing antibodies, we purified the S1 trimer protein expressed by the MVA/S1 vaccine and determined its ability to bind to human ACE2 using biolayer interferometry (BLI) (Figure S2). We found that the affinity of S1 for ACE2 decreased by 5-fold when the protein was incubated at 25°C for 60 min, and this was not the case for the RBD. These data indicate the unstable nature of the RBD in S1 because the association with ACE2 protein is decreased upon prolonged incubation at room temperature.

The MVA/S and MVA/S1 vaccines induce strong T cell responses in the spleen and lungs of mice

To determine T cell responses, we stimulated lymphocytes from the spleens and lungs of vaccinated mice with overlapping peptide pools specific to the RBD, S1, and S2 regions of the spike protein and measured the frequency of interferon γ (IFNγ)+ CD4 and CD8 T cells using the intracellular cytokine staining (ICS) assay. Both vaccines induced comparable IFNγ+ CD8 and CD4 T cell responses that primarily targeted the S1 region (including the RBD) in the spleen (Figure 3A) and lungs (Figure 3B). We next studied whether vaccination induced formation of inducible bronchus-associated lymphoid tissue (iBALT), which has been shown to provide protection against influenza infection in the absence of peripheral lymphoid organs in mice (Moyron-Quiroz et al., 2004; Woodland and Randall, 2004) using immunohistochemistry 3 weeks after MVA boost by staining for B and T cells (Figures 3C and 3D). As expected, naive mice showed very little or no iBALT; however, MVA/S-vaccinated
mice showed significant induction of iBALT, indicating generation of local lymphoid tissue. Formation of iBALT was also evident in the MVA/S1 group, but to a lesser extent. The relatively lower iBALT response in the MVA/S1 group could be due to the overall lower spike-specific antibody response induced in MVA/S1 mice compared with MVA/S mice. Although we do not know the longevity or persistence of these BALTs, they are expected to help with rapid expansion of immunity in the lungs following exposure to SARS-CoV-2 (Moyron-Quiroz et al., 2004; Wiley et al., 2009).

The MVA/S vaccine induces a strong neutralizing antibody response with effector functions and CD8 T cell response in rhesus macaques

To test the immunogenicity and protective ability of the MVA/S vaccine, we immunized rhesus macaques (n = 5/group) with the MVA/S vaccine or MVA/wild type (WT) vaccine delivered intramuscularly at weeks 0 and 4 with a dose of $1 \times 10^8$ plaque-forming units (PFUs) (Figure 4A). At week 8 (4 weeks after the boost), animals were challenged intranasally and intratracheally with live SARS-CoV-2 virus. Consistent with the data for mice, two MVA/S vaccinations induced a strong binding antibody against RBD (geometric mean titer of $2.4 \times 10^4$) and total S (geometric mean titer of $1.5 \times 10^5$) that persisted until 4 weeks after the boost (Figure 4B). IgG subclass analysis revealed the majority of the response as IgG1, indicating a Th1-dominant response (Figure 4C). We also detected a low titer of spike-specific IgA (Figure 4C). The MVA/S vaccine-induced antibody showed strong neutralization of live virus 2 weeks after boost, with a geometric mean titer of 177 (range, 90–516) (Figure 4D). A similar neutralization titer was also observed in a spike (having the D614G mutation) pseudotyped virus neutralization assay (Figure 4E). A low titer of neutralizing antibodies was detectable in 2 of the 5 animals after prime (Figure 4D). Antibody binding to the RBD correlated directly with live virus neutralization (Figure 4F). In addition to the neutralizing activity, the vaccine-induced sera showed strong antibody-dependent complement deposition (ADCD) activity and low antibody-dependent neutrophil phagocytosis (ADCP) and antibody-dependent neutrophil phagocytosis (ADNP) activity (Figure 4G).
The MVA/S vaccine also generated a strong spike-specific IFN\(\gamma\)+ CD8 T cell response that was evident as early as 1 week after the priming immunization (Figure 4H). The frequency of CD8 T cell responses was not boosted further following the second MVA/S immunization. Vaccine-induced CD8 T cells were also positive for tumor necrosis factor alpha (TNF-\(\alpha\)) and interleukin-2 (IL-2) and negative for IL-17 (Figure 4I). The MVA/S vaccine induced very low frequencies of IFN\(\gamma\)+ CD4 T cells (data not shown). These data demonstrate that MVA/S vaccinations induce a poly-functional CD8 T cell response capable of producing IFN\(\gamma\), IL-2, and TNF-\(\alpha\) in macaques.

MVA/S vaccination provides protection from SARS-CoV2 infection and replication in the lungs

Following intranasal and intratracheal challenge, we monitored for subgenomic viral RNA to distinguish the replicating virus from the inoculum in the lungs (BAL fluid), nasopharynx, and throat on days 2, 4, 7, and 10 (day of euthanasia) (Figure 5). On day 2, all 5 controls (MVA/Wt vaccinated) tested positive for virus in BAL fluid and the throat, and 3 of 5 tested positive in the nasopharynx, indicating that all animals were infected productively (Figure 5A). The viral RNA titer was variable and ranged from \(10^2\)–\(7 \times 10^6\) copies/mL. These titers were maintained in the BAL fluid until day 4 and then declined quickly with time in all animals (except for one). The MVA/S vaccination completely prevented the replication of SARS-CoV2 in the lungs (Figure 5B).
in BAL fluid from one animal) and were below our detection limit by day 10. In contrast, MVA/S-vaccinated animals rapidly controlled SARS-CoV-2 replication in the lungs on day 2 (p < 0.05) and day 4 (p < 0.05) compared with controls (Figure 5A), with 4 of the 5 vaccinated animals being negative in BAL fluid. However, in the throat, all vaccinated animals tested negative on day 2 (p < 0.01), but a low titer of virus replication was evident in one or two vaccinated animals on days 4 and 7. Similarly, in the nasopharynx, one or two animals showed virus replication on days 2, 4, and 7, and virus replication was not significantly different between controls and

Figure 5. The MVA/S vaccine protects from SARS-CoV-2 infection and replication and reduces lung pathology in rhesus macaques.

Following vaccination, all macaques were challenged with SARS-CoV-2 at week 8 by intratracheal (IT) and intranasal (IN) route. Virus replication, lung pathology, binding and neutralizing antibody titers, and T cell responses were measured.

(A) SARS-CoV-2 subgenomic viral RNA in the lung (BAL fluid), throat, and nasopharynx on days 2, 4, 7, and 10 (day of euthanasia) after infection.

(B and C) Lung pathology on day 10 after infection. Shown is hematoxylin and eosin (H&E) staining of lung sections to analyze tissue structure and cell infiltration (B) and lung pathology score (C). See Table S1 for details.

(D and E) SARS-CoV-2 RBD-specific serum IgG responses (D) and live SARS-CoV-2 neutralization (E) in serum following challenge.

(F) IFNγ+ CD8+ and CD4+ T cells in blood on day 10 after infection after re-stimulation with a peptide pool specific to the indicated protein. S1, S1 region of spike; S2, S2 region of spike; NC, nucleocapsid; Sum, total response (S1+S2+NC). Bars and columns show mean responses in each group ± SEM; Mann-Whitney test: *p < 0.05, **p < 0.01. Dotted lines reflect the limit of detection. See also Figure S3 and Table S1 for details.
Figure 6. Innate and adaptive immune responses after SARS-CoV-2 challenge in the lungs of rhesus macaques
Following SARS-CoV-2 infection, BAL fluid was collected on days 4, 7, and 10, and various innate cells were analyzed. On day 10 (at euthanasia), B cells were analyzed in BAL fluid, and GC-Tfh and GC-B cells were analyzed in hilar LNs. n = 5/group, except for the MVA/S group on day 4, where data for one animal were not available. These analyses were performed only once because the macaque study was done only once.

(legend continued on next page)
vaccinated animals at all time points. By day 10, all control and vaccinated animals were negative in all 3 compartments. These results demonstrate that MVA/S vaccination provides protection from SARS-CoV2 infection and replication in the lower respiratory tract.

Consistent with early virus control in the lungs, vaccinated animals also showed lower lung pathology compared with control animals (Figure 5B). To assess lung pathology, we analyzed multiple regions of upper, middle, and lower lung lobes at euthanasia. Lung pathology analyses and scoring (considering severity and the number of affected lobes) were performed by two independent pathologists in a blinded fashion. The total pathology score was lower in the vaccinated group compared with the control group. Specifically, MVA/S-vaccinated animals showed decreased type 2 pneumocyte hyperplasia, peribronchiolar hyperplasia, alveolar septal thickening, and inflammatory cell infiltration (Figures 5B, Figure S3). Overall, these data support a beneficial role of MVA/S vaccination in reducing lung pathology. We also performed histopathological examination of various other tissue samples, including nasal turbinates, trachea, tonsils, hilar lymph nodes, spleen, heart, gastrointestinal tract (stomach, jejunum, ileum, colon, and rectum), and testes. We did not observe significant histological lesions in upper respiratory tract tissues (nasal turbinates and trachea) and other examined tissues in control and vaccinated animals.

To understand the anamnestic expansion of antibodies and T cells after infection, we measured binding and neutralizing antibodies in serum on days 0, 4, 7, and 10 and T cells in the blood on day 10. Some of the control animals developed a low titer of binding and virus-neutralizing activity by day 10 that was markedly lower compared with the titers in vaccinated animals (Figures 5D and 5E). The neutralizing antibody titer in vaccinated animals was maintained in 2 animals and increased by 4-fold in 2 animals and by 25-fold in 1 animal. The control animals also showed IFNγ+ CD8 and CD4 T cells in the blood that were largely specific to S1 and nucleocapsid (NC) (Figure 5F). However, the vaccinated animals mainly showed IFNγ+ CD8 T cells against S1 but not NC. The S1-specific response in vaccinated animals after infection was likely due to the persisting vaccine-induced CD8 T cells. However, the lack of an NC-specific CD8 T cell response suggests that these animals were not exposed to a significant amount of the NC protein made by the replicating virus after infection. Thus, post-infection immune responses pointed to a less systemic spread of virus replication, at least in some of the vaccinated animals.

MVA/S vaccination protects from infection-induced immune abnormalities in the lungs

To further understand the influence of infection and vaccine protection on innate and adaptive immunity in the lungs early after infection, we monitored various innate cells and B cells in BAL fluid and Germinal Center - T follicular helper (GC-Tfh) and GC-B cell responses in lung draining hilar lymph nodes (LN) on day 10 after infection (Figure 6A). Longitudinal analysis of innate cells on days 4, 7, and 10 after infection in control (MVA/Wt) animals revealed a significant increase in the frequency of macrophages on day 7, followed by decline on day 10 (Figure 6B). In contrast to macrophages, the frequency of total Human Leukocyte Antigen-DR+ (HLA-DR+) dendritic cells (DCs) and plasmacytoid DCs (pDCs) on day 7 were higher in controls compared with MVA/S-vaccinated animals and decreased over time until day 10 (Figures 6C and 6D). The frequency of BDCA-1+ DCs and myeloid-derived DCs (MDCs) increased by day 7 and declined by day 10, and the frequency of natural killer (NK) cells increased gradually until day 10 (Figure 6D). However, the frequency of all of these cells stayed relatively stable in vaccinated (MVA/S) animals on days 4–10, except BDCA-1+ DCs, which showed a small increase on day 10 compared with day 4. On day 10, the control animals showed a lower frequency of HLA-DR+ DCs compared with vaccinated animals that was also reflected in the frequency of pDCs and BDCA-1+ DCs. Longitudinal analysis of innate cells revealed expansion and contraction of all studied subsets, but with different kinetics in controls but not in vaccinated animals, presumably because of high virus replication in controls. These data also suggest that there was a potential loss of some of the DCs in controls by day 10. It is difficult to determine this in the absence of data on pre-infection frequencies of innate cells in BAL fluid. In addition, B cells in the controls showed lower expression of HLA-DR, suggesting an impaired B cell response (Figure 6E; Titanji et al., 2010). Furthermore, the frequency of total (Figure 6F) and CXCR5+ GC-Tfh (Figure 6G) and GC-B cells (Figure 6H) in hilar LNs was higher in control animals compared with vaccinated animals, suggesting a higher antigen load and proinflammatory environment in the former. These results demonstrate distinct innate and adaptive immune profiles in the lungs between control and MVA/S-vaccinated animals that point to a lower antigen load and inflammation in vaccinated animals early after infection.

MVA/S vaccination reduces transcripts associated with inflammation and hyperimmune activation in lung macrophages

SARS-CoV-2 infection of non-human primates (NHPs), in most cases, does not recapitulate the full spectrum of clinical symptoms of severe COVID-19, with animals typically exhibiting a more moderate phenotype (Hartman et al., 2020; Munster et al., 2020). Recently, however, we and others have observed that SARS-CoV-2 infection of rhesus macaques (Aid et al., 2020; Hoang et al., 2021) and African green monkeys (AGMs)
Figure 7. MVA/S vaccination against SARS-CoV-2 protects from lower airway inflammation in BAL fluid on day 4

Single-cell suspensions from BAL fluid on day 4 after SARS-CoV-2 infection were collected from MVA/S-vaccinated (n = 4) and MVA/Wt control (n = 5) macaques and subjected to single-cell RNA seq. These analyses were performed only once because the macaque study was done only once.

(legend continued on next page)
elicits many of the immunopathological events in the airway (elevated inflammatory cytokines and chemokines and recruitment of monocytes and neutrophils) that have been reported in the airways of individuals exhibiting severe COVID-19 symptoms (Liao et al., 2020). To assess the effect of our vaccine on these inflammatory sequelae in the airway, we performed single-cell RNA sequencing (RNA-seq) on the cellular fraction recovered from BAL fluid on day 4 after infection (Figure 7). The vast majority of cells identified in the BAL fluid were CD68+ myeloid cells (82% in controls and 71% in vaccinated animals), followed by CD8+ T cells (7% in controls and 14% in vaccinated animals) and minor populations (<5%) consisting of B cells, DCs, and epithelial cells (Figures 7A and 7B; Figure S4). Consistent with concurrent studies by us and others using NHPs, inoculation of NHPs with SARS-CoV-2 led to widespread induction of IFN-stimulated genes (ISGs) and related pathways as early as day 4 after infection, prevalently in the myeloid population (Aid et al., 2020; Hoang et al., 2021; Speranza et al., 2020; Figures 7C and 7G). However, we observed that expression of transcripts associated with ISGs was attenuated in vaccinated animals at the individual gene level and pathway level (Figures 7C and 7G). In human and NHP studies, SARS-CoV-2 has been observed to induce strong expression of inflammatory cytokines and chemokines in myeloid-origin cells in the BAL fluid and lungs (Hoang et al., 2021; Liao et al., 2020; Speranza et al., 2020). In the current study, control animals largely recapitulated these findings; we observed high expression of transcripts associated with IL-6, TNF-α, and IL-1β production (Figures 7D–7F). We also noted widespread expression of CXCL8, CXCL9, CXCL10, CXCL11, CCL8, and CCL19 (Figures 7D–7F). In vaccinated animals, expression of IL-6, TNF-α, IL-1β, CXCL8, and CXCL10 was reduced compared with controls (Figures 7D–7F). Recent studies in AGMs have reported that SARS-CoV-2 infection elicits a population shift within the myeloid fraction in which interstitial macrophages/infiltrating monocytes (identified by lack of the macrophage receptor with collagenous structure (MARCO) cell marker) become predominant over MARCO+ resident alveolar macrophage (Speranza et al., 2020). Here we observed that vaccinated animals trended toward a higher proportion of MARCO+ cells relative to unvaccinated controls (70% versus 54%), indicating reduced recruitment of monocytes/interstitial macrophages (Figures 7E and 7F). In addition, expression of C1QB and C1QC, components of the C1q complement receptor, was also higher in control macrophages (Figures 7D and 7F). Furthermore, the transcripts associated with activating FcγR1A (required for the effector functions of IgG1 and IgG3) was lower and inhibitory FcγR2B was higher in controls (Figure 7D). These data demonstrate that MVA/S vaccination is able to reduce inflammatory events in the airway, including reduced infiltration of activated monocytes and lower production of inflammatory cytokines/chemokines. Additionally, our observation of attenuated expression of ISGs in the cellular fraction of BAL fluid of vaccinated animals provides orthogonal validation of the ability of MVA/S vaccination to reduce airway SARS-CoV-2 virus replication.

**DISCUSSION**

There is an urgent global need for development of a safe and effective COVID-19 vaccine. Humoral and cell-mediated immune responses in systemic and mucosal compartments are crucial for preventing infection and counteracting virus replication. We focused our efforts on development of MVA-based vaccines for COVID-19 based on our nearly 20 years of experience with development of MVA-based vaccines for HIV (Chea and Amara, 2017; Robinson and Amara, 2005), which has demonstrated that MVA is safe in people (Goepfert et al., 2014), including HIV-infected individuals (Thompson et al., 2016), and induces strong humoral and cellular immunity that is long lasting (Goepfert et al., 2014; Nigam et al., 2007). Our results showed that two doses of recombinant MVA (rMVA) expressing the membrane-anchored prefusion stabilized full-spike protein can induce a strong neutralizing antibody against SARS-CoV-2 and the highly infectious D614G variant (Korber et al., 2020) and a CD8 T cell response and provides protection from SARS-CoV-2 replication in the lungs (lower respiratory tract). In addition, vaccination blunted virus replication very early on day 2 in the throat. Notably, hematoxylin and eosin staining analysis in individual vaccinated (MVA/S) animals showed that MVA/S vaccination retained healthy lung features, like thin alveolar septa, perivascular cuffing, peribronchiolar hyperplasia, and no inflammatory cells (except in one animal, few inflammatory cells were observed) in alveoli compared with control (MVA/Wt) animals. The effects of vaccination on protection in the nasopharynx was inconclusive because of the large variation of viral load in the control group and relatively small group sizes. Our results also showed that vaccination can provide protection from inflammation, Th1-biased hyperimmune activation, and immune dysfunction in the lung very early after infection.

We found that MVA expressing soluble trimeric S1 protein does not induce a neutralizing antibody response despite containing the RBD and inducing strong S1-binding antibodies. This suggests that the specificity of the antibody response induced by the S1 immunogen may be distinct from that induced by the S immunogen. This was also suggested by the distinct
RBD- and S1-specific humoral immune profiles in the MVA/S and MVA/S1 groups, where the MVA/S immunization yielded a stronger RBD-specific IgG response, whereas MVA/S1 induced a stronger S1-specific response. This was unexpected, given the fact that RBD is part of S1. It will be important to understand the mechanisms that lead to loss of neutralization when MVA/S1 is used as an immunogen. We will also be important to study whether the antibody response induced by the MVA/S1 vaccine possesses any kind of antibody-dependent enhancement of infection activity. Our preliminary data in this direction point to the inability of the S1 protein to retain binding to ACE2 during prolonged incubation at room temperature. This could have contributed to induction of strong binding antibodies to regions in S1 other than the RBD following immunization. Further studies are needed to understand the binding specificity of antibodies induced by these two vaccines.

Our study demonstrated that vaccination can protect from infection-induced inflammation, Th1-biased hyperimmune activation, and humoral immune dysfunction in the lungs at the single-cell level when the virus is still actively replicating very early (day 4) after infection. Although a recent COVID-19 vaccine study demonstrated that vaccination can reduce inflammation in the lung by measuring selected cytokines, we were able to show these findings at the single-cell level in lung-resident macrophages using cutting-edge technologies. Single-cell RNA-seq allowed us study several hundred genes, including ISGs and immune function-associated genes, and specific cell subsets that contributed to inflammation and altered expression. SARS-CoV-2 infection, despite being largely an acute infection in this model, can cause significant inflammation, Th1-biased hyperimmune activation, and immune dysfunction, such as loss of HLA-DR expression on B cells and lower expression of activating (FcγR1A) and higher expression of inhibitory (FcγR2B) FcγRs, which can potentially lead to diminished effector functions of IgG1 and IgG3. These results are important because they demonstrate that systemic vaccination can provide protection from infection-induced immune abnormalities in the lungs very early (day 4) after infection. Although our preliminary analyses made important findings, future analyses will dig deeper into identification of individual clusters of cell populations within myeloid cells and see how they differ between control and vaccinated animals after infection.

It will be good to compare the immunogenicity and protective ability of the MVA/S vaccine with those of other vaccines that are based on mRNA, adenoviruses (Ad) (chimpanzee or Ad26), and proteins that have already been approved or are currently being tested in human trials (Brouwer et al., 2021; Corbett et al., 2020; Gao et al., 2020; Keech et al., 2020; Krammer, 2020; Laczkó et al., 2020; Mercado et al., 2020; Poland et al., 2020; Sahin et al., 2020; Smith et al., 2020; Tostanoski et al., 2020; van Doremalen et al., 2020; Walls et al., 2020; Yu et al., 2020). However, it is difficult to do so because different studies used different neutralization assays that can provide different results. In addition, some studies reported a 50% neutralization titers and others 80%—90%. Similarly, for protection studies, different stocks and doses of viruses and species of macaques are used. Because of these limitations, we refrain from making any comparisons between studies. However, it is clear that some of the protein-based vaccines with potent adjuvants (Brouwer et al., 2021; Walls et al., 2020) have induced much stronger neutralizing antibody responses compared with viral vector-based vaccines, including our MVA/S vaccine. In contrast to viral vector-based vaccines, protein-based vaccines induce a poor CD8 T cell response. In addition, it is important to compare the durability of these responses between different vaccines. Acknowledging the different conditions of viral challenges being used, the protection we observed in this study is quite comparable with most of the vaccines that have already been advanced into the clinic.

In conclusion, these results demonstrate that MVA/S vaccination can provide protection from intranasal and intratracheal SARS-CoV-2 challenge and support further development of this vaccine to test immunogenicity and efficacy in humans. They also suggest that the MVA/S vaccines can serve as an excellent boosting agent for COVID-19 vaccines based on mRNA, DNA, and chimpanzee adenovirus and Ad26 to boost cellular and humoral immunity.

Limitations of study

Although these results are encouraging, future studies will be necessary to determine the longevity of vaccine-induced immunity and durability of protection using larger groups. This is important because this vaccine is being developed for human use. It is encouraging to see that the MVA/S vaccine-induced antibody response contracted only minimally (less than 2-fold) between weeks 2 and 4 after boost, when maximum contraction of the antibody response happens (Kannanganat et al., 2016; Nigam et al., 2007). This, combined with our prior studies demonstrates the longevity of MVA vaccine-induced immunity in humans (Goepfert et al., 2014) and NHPs (Nigam et al., 2007). It is highly likely that the MVA/S-based vaccine will provide durable protection.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Ethics Statements
  - Cells and Viruses
  - Animal models
- **METHOD DETAILS**
  - Construction and characterization of MVA vaccines
  - Flow staining for SARS-CoV-2 Spike protein expression
  - Protein expression and purification
  - Western Blotting
  - Animal Vaccination
  - SARS-CoV-2 Challenge of rhesus macaques
  - Binding antibody responses using ELISA
  - Live-virus neutralization
  - Pseudovirus neutralization assay
  - Antibody isotype, IgG subclass and FcR binding of mouse sera
SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.immuni.2021.02.001.

ACKNOWLEDGMENTS

We thank Traci H. Legere, Brenda Wehrle, and Zeba S. Momir for help with processing blood and tissue samples, Drs. Bernard Moss and Lynda Wyatt for providing the pLW73 transfer plasmid, the Yerkes Division of Pathology and Research Resources for outstanding animal care during the pandemic, and the Histology and Molecular Pathology Lab for help with tissue sectioning. The following reagents was produced under HHSN272201400008C and obtained through BEI Resources, NIAID: NIH: vector pCAGGS containing the SARS-related coronavirus 2, Wuhan-Hu-1 spike glycoprotein RBD, NR-52309. Imaging for this research project was supported in part by the Emory University Integrated Cellular Imaging Microscopy Core. The content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institute of Health. This work was supported in part by National Institutes of Health grant RO1 AI48378-01S and Fast Grants award 2166 (to R.R.A) and NCCR/NIH base grant P51 OD011132 to YNPRC. Next-generation sequencing services were provided by the Yerkes NHP Genomics Core, which is supported in part by NIH P51 OD011132. Sequencing data were acquired on an Illumina NovaSeq6000 funded by NIH S10 OD026799 (to S.E.B.).

AUTHOR CONTRIBUTIONS

R.R.A. was responsible for the overall experimental design and supervision of laboratory studies and manuscript writing and editing. Sailaja Gangadhara developed, constructed, and characterized the mVA/S and MVA/S1 vaccines and provided vaccine stocks for animal studies. N.K.R., Sailaja Gangadhara, N.C., Ayalnesh Shiferaw, V.S.B., A.K.B., S.A.R., Anusmita Sahoo, V.V.E., L.L., K.F., S.W., S.F., C.A., A.A.U., and K.P. were responsible for conducting experiments, data collection, and data analysis. M.S.S. conducted and supervised live virus neutralizing antibody assays. D.M. supervised pseudovirus neutralizing antibody assays. J.C., S.M.J., J.S.W., F.C.-S., and R.L.S. provided veterinary support in ABSL-3. G.A. supervised the Luminex assays. Neutralizing antibody assays. J.C., S.M.J., J.S.W., F.C.-S., and R.L.S. contributed to manuscript writing and editing.

DECLARATION OF INTERESTS

R.R.A., Sailaja Gangadhara, and N.K.R. are co-inventors of the mVA/S vaccine technology. Emory University filed a patent on this technology. R.R.A. serves as a SAB member for Heat Biologics Inc.

Received: October 23, 2020
Revised: December 4, 2020
Accepted: January 29, 2021
Published: February 23, 2021

REFERENCES

Ackerman, M.E., Moldt, B., Wyatt, R.T., Dougast, A.-S., McAndrew, E., Tsoukas, S., Jost, S., Berger, C.T., Sciaranghella, G., Liu, Q., Irvine, D.J., Burton, D.R., and Alter, G. (2011). A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 366, 8–19.

Aid, M., Busman-Sahay, K., Vidal, S.J., Maliga, Z., Bondoc, S., Starke, C., Terry, M., Jacobson, C.A., Wrijl, L., Ducat, S., et al. (2020). Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rheus Macaques. Cell 183, 1354–1368.e113.

Amara, R.R., Villinger, F., Altmann, J.D., Lydy, S.L., O’Neil, S.P., Staprans, S.I., Montefiori, D.C., Xu, Y., Herndon, J.G., Wyatt, L.S., et al. (2001). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74.

Amara, R.R., Villinger, F., Staprans, S.I., Altmann, J.D., Montefiori, D.C., Kozyr, N.L., Xu, Y., Wyatt, L.S., Earl, P.L., Herndon, J.G., et al. (2002). Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 76, 7625–7631.

Aran, D., Looney, A.P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R.P., Wothers, P.J., Abate, A.R., et al. (2019). Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172.

Barouch, D.H., Li, H., Li, H., Maxfield, L.F., Abbink, P., Lynch, D.M., lampietto, M.J., SanMiguel, A., Seaman, M.S., Ferrari, G., et al. (2012). Vaccine protection against acquisition of neutralization-resistant HIV challenges in rhesus monkeys. Nature 482, 89–93.

Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, P.L., Murphy, B.R., Subbarao, K., and Moss, B. (2004). Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA 101, 6641–6646.

Braut, A.C., Domi, A., McDonald, E.M., Talmi-Frank, D., McCurley, N., Basu, R., Robinson, H.L., Hellerstein, M., Duggal, N.K., Bowen, R.A., and Guirakhoo, F. (2017). A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model. Sci. Rep. 7, 14769.

Brouwer, P.J.M., Brinkkemper, M., Maisonnasse, P., Dereudre-Bosquet, N., Grobben, M., Claireaux, M., de Gast, M., Marlin, R., Chesnais, V., Diry, S., et al. (2021). Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Nature. Published online February 1, 2021. https://doi.org/10.1038/s41586-021-03275-y.

Brown, E.P., Dowell, K.G., Boesch, A.W., Normandin, E., Mahan, A.E., Chu, T., Barouch, D.H., Bailey-Kellog, C., Alter, G., and Ackerman, M.E. (2017). Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. J Immunol Methods 443, 33–44.

Brown, E.P., Licht, A.F., Dugast, A.S., Choi, I., Bailey-Kellog, C., Alter, G., and Ackerman, M.E. (2012). High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J. Immunol. Methods 386, 117–123.

Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420.

Chamcha, V., Jones, A., Quigley, B.R., Scott, J.R., and Amara, R.R. (2015). Oral Immunization with a Recombinant Lactobacillus lactis-Expressing HIV-1 Antigen on Group A Streptococcus Pilus Induces Strong Mucosal Immunity in the Gut. J. Immunol. 195, 5025–5034.

Chan, J.F., Lau, S.K., To, K.K., Cheng, V.C., Woo, P.C., and Yuen, K.Y. (2015). Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28, 465–522.

Chea, L.S., and Amara, R.R. (2017). Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models. Expert Rev. Vaccines 16, 973–985.

Chea, L.S., Wyatt, L.S., Gangadhara, S., Moss, B., and Amara, R.R. (2019). Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses. J. Virol. 93, 93.
Speranza, E., Williamson, B.N., Feldmann, F., Sturdevant, G.L., Pérez-Pérez, L., Mead-White, K., Smith, B.J., Loviglio, J., Martens, C., Munster, V.J., et al. (2020). SARS-CoV-2 infection dynamics in lungs of African green monkeys. bioRxiv. https://doi.org/10.1101/2020.08.20.258087.

Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., 3rd, Hao, Y., Stocekosis, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell Data. Cell 177, 1888–1902.e21.

Suthar, M.S., Zimmerman, M., Kaufman, R., Mantsus, G., Linderman, S., Vanderheiden, A., Nyhoff, L., Davis, A., Adekunle, S., Affer, M., et al. (2020). Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep. Med. 1, 100040.

Thompson, M., Heath, S.L., Sweeton, B., Williams, K., Cunningham, P., Keere, B.F., Sen, S., Palmer, B.E., Chomont, N., Xu, Y., et al. (2016). DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus. PLoS ONE 11, e0163164.

Tianji, K., Velu, V., Chenmreddi, L., Vijay-Kumar, M., Gewirtz, A.T., Freeman, G.J., and Amara, R.R. (2010). Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J. Clin. Invest. 120, 3878–3890.

Tostanoski, L.H., Wegmann, F., Martinot, A.J., Loos, C., McMahan, K., Mercado, N.B., Yu, J., Chan, C.N., Bondoc, S., Starke, C.E., et al. (2020). Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat. Med. 26, 1694–1700.

van Doremalen, N., Lamb, T., Spencer, A., Beli-J-Ramsterforser, S., Purushotham, J.N., Port, J.R., Avanzato, V., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020). ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv. https://doi.org/10.1101/2020.05.05.031195.

Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.L., Abiona, O., Graham, B.S., and McLellan, J.S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263.

Woelfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Muller, M.A., Niemeyer, D., Jones, T.C., Vollmar, P., Rothe, C., et al. (2020). Virological assessment of hospitalized patients with COVID-19. Nature 587, 465–469.

Woodland, D.L., and Randall, T.D. (2004). Anatomical features of anti-viral immunity in the respiratory tract. Semin. Immunol. 16, 163–170.

Yu, J., Tostanoski, L.H., Peter, L., Mercado, N.B., McMahan, K., Mahrokhian, B., Liu, J., Schindewolf, C., Bopp, N.E., Aguilar, P.V., et al. (2020). An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 841–848.e3.

Yu, J., Jia, W., Wang, P., Zhang, S., Shi, X., Wang, X., and Zhang, L. (2019). Antibodies and vaccines against Middle East respiratory syndrome coronavirus. Emerg. Microbes Infect. 8, 841–856.

Yong, C.Y., Ong, H.K., Yeap, S.K., Ho, K.L., and Tan, W.S. (2019). Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus. Front. Microbiol. 10, 1781.

Yu, J., Tostanoski, L.H., Peter, L., Mercado, N.B., McMahan, K., Mahrokhian, S.H., Nikolova, J.P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020). DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806–811.

Zhang, B., Kirov, S., and Snoddy, J. (2005). WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 33, W741–8.

Zhang, Z.Z., Jiang, C.L., Yu, H.X., Lou, C.P., Zhao, D.H., Wu, Y.G., Jin, Y.H., Liu, C.S., and Kong, W. (2007). Immunogenicity of lyophilized MVA vaccine for HIV-1 in mice model. Chem. Res. Chin. Univ. 23, 329–332.

Wyatt, L.S., Earl, P.L., Liu, J.Y., Smith, J.M., Montefiori, D.C., Robinson, H.L., and Moss, B. (2004). Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. AIDS Res. Hum. Retroviruses 20, 645–653.

Xie, X., Munuato, A., Lokugamage, K.G., Narayanan, K., Zhang, X.Z., Zou, J., Liu, J., Schindewolf, C., Bopp, N.E., Aguilar, P.V., et al. (2020). An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 841–848.e3.

Xu, J., Jia, W., Wang, P., Zhang, S., Shi, X., Wang, X., and Zhang, L. (2019). Antibodies and vaccines against Middle East respiratory syndrome coronavirus. Emerg. Microbes Infect. 8, 841–856.

Yong, C.Y., Ong, H.K., Yeap, S.K., Ho, K.L., and Tan, W.S. (2019). Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus. Front. Microbiol. 10, 1781.

Yu, J., Tostanoski, L.H., Peter, L., Mercado, N.B., McMahan, K., Mahrokhian, S.H., Nikolova, J.P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020). DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806–811.

Zhang, B., Kirov, S., and Snoddy, J. (2005). WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 33, W741–8.

Zhang, Z.Z., Jiang, C.L., Yu, H.X., Lou, C.P., Zhao, D.H., Wu, Y.G., Jin, Y.H., Liu, C.S., and Kong, W. (2007). Immunogenicity of lyophilized MVA vaccine for HIV-1 in mice model. Chem. Res. Chin. Univ. 23, 329–332.
## KEY RESOURCES TABLE

| REAGENT or RESOURCE                  | SOURCE                        | IDENTIFIER                  |
|--------------------------------------|-------------------------------|-----------------------------|
| Antibodies                           |                               |                             |
| APC Goat Anti-Mouse Ig (Multiple Adsorption) Clone Polyclonal (RUO) | BD PharMingen | Cat#550826; RRID:AB_398465 |
| PE Donkey anti-rabbit IgG (minimal x-reactivity) Antibody | BioLegend | Cat#406421; RRID:AB_2563484 |
| Alexa Fluor® 700 Rat Anti-Mouse CD4 | BD Biosciences | Cat#557956; RRID:AB_396956 |
| PE Rat Anti-Mouse CD8a               | BD Biosciences | Cat#553032; RRID:AB_394570 |
| BV 711 anti-mouse TNF-α Antibody     | BioLegend | Cat#506349; RRID:AB_2629800 |
| FITC Rat Anti-Mouse IFN-γ            | BD Biosciences | Cat#554411; RRID:AB_395375 |
| APC Rat Anti-Mouse IL-2              | BD Biosciences | Cat#554429; RRID:AB_398555 |
| SARS-CoV-2 (COVID-19) spike antibody | GenTex | Cat#GTX135356; RRID:AB_2867482 |
| SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A8] | GenTex | Cat#GTX632604; RRID:AB_2864418 |
| SARS-CoV-2 (2019-nCoV) Spike RBD Antibody, Rabbit PAb, Antigen Affinity Purified | Sino Biologicals | Cat#40592-T62 |
| Monoclonal Anti-Vaccinia Virus E3L, Clone TW2.3 | BEI Resources | Cat#NR-4547 |
| anti-CD28/CD49d antibodies           | BD Biosciences | Cat#557393; RRID:AB_396676 |
| anti-CD28                             | BD Biosciences | Cat#555725; RRID:AB_396068 |
| anti-CD49d                            | BD Biosciences | Cat#555501; RRID:AB_2130052 |
| anti-CD3-PE-Texas Red                | BD Biosciences | Cat#562406; RRID:AB_11154406 |
| anti-CD8-BV510                        | BD Biosciences | N/A - Custom reagent       |
| Live/Dead-APC-Cy7                     | Invitrogen                  | Cat#L34976                  |
| anti-IFN-γ-V450                      | BD Biosciences | Cat#560371; RRID:AB_1645594 |
| anti-TNF-α-A700                       | BD Biosciences | Cat#557996; RRID:AB_396978 |
| anti-IL-2-PE-Cy7                      | BD Biosciences | Cat#560707; RRID:AB_1727542 |
| anti-IL-17-FITC                      | EBio                        | Cat#11-7179-42; RRID:AB_10805390 |
| anti-NKG2A-APC                        | Miterry biotech            | Cat#130-113-583; RRID:AB_2726170 |
| anti-HLA-DR-PerCP                     | BD Biosciences | Cat#347364; RRID:AB_400292 |
| anti-CD163-efflor 450                 | Thermo scientific          | Cat#48-1637-42; RRID:AB_2811826 |
| anti-BOCA1-BV711                      | BioLegend                  | Cat#331538; RRID:AB_2629760 |
| anti-CD11C-BV650                      | BioLegend                  | Cat#301638; RRID:AB_2567397 |
| anti-CD122-PEcy7                      | BD biosciences            | Cat#560826; RRID:AB_10563898 |
| anti-CD11b-PE/Dazzle 594              | BioLegend                  | Cat#301348; RRID:AB_2564081 |
| anti-CD3-BV605                        | BD biosciences            | Cat#562994; RRID:AB_2737938 |
| anti-CD20-BV605                       | BioLegend                  | Cat#302334; RRID:AB_2563398 |
| anti-Ki67-BV786                       | BD Biosciences            | Cat#563756; RRID:AB_2732007 |
| anti-CD3-AN700                        | BD Biosciences            | Cat#557917; RRID:AB_396938 |
| anti-CD21-BUV737                      | BD Biosciences            | Cat#612788                  |
| anti-CD3-PerCP                        | BD Biosciences            | Cat#552851; RRID:AB_394492 |
| anti-CD8-BV711                        | BioLegend                  | Cat#344734; RRID:AB_2565243 |
| anti-CXCR5-PE                         | Invitrogen                  | Cat#12-9185-42; RRID:AB_11219877 |
| anti-PD1-BV421                        | BioLegend                  | Cat#329920; RRID:AB_10900818 |
| anti-Ki67-PEcy7                       | BD Biosciences            | Cat#561283; RRID:AB_10716060 |
| anti-BCL6-PE-CF594                    | BD Biosciences            | Cat#562401; RRID:AB_11152084 |
| anti-CD27-BUV496                      | BD Biosciences            | Cat#751678; RRID:AB_2875664 |

(Continued on next page)
Continued

**REAGENT or RESOURCE** | **SOURCE** | **IDENTIFIER**
--- | --- | ---
**Bacterial and virus strains**

NEB® Stable Competent E. coli (High Efficiency) | NEB | Cat#C3040H

MVA/S (Modified Vaccinia virus Ankara) – Spike full-length with prefusion stabilized mutants | This paper | N/A

MVA/S1 (Modified Vaccinia virus Ankara) – S1 | This paper | N/A

MVA/Wt (Modified Vaccinia virus Ankara wild-type) | This paper | N/A

SARS-CoV-2 (icSARS-CoV-2) | provided by Mehul Suthar, Emory University | N/A

mNeonGreen SARS-CoV-2 (2019-nCoV/USA_WA1/2020) | Provided by Yong Shi, The University of Texas Medical Branch | N/A

**MVA/S (Modified Vaccinia virus Ankara) – Spike full-length with prefusion stabilized mutants** | This paper | N/A

**SARS-CoV-2 (2019-nCoV/USA_WA1/2020)** | Provided by Yong Shi, The University of Texas Medical Branch | N/A

**MVA/Wt (Modified Vaccinia virus Ankara wild-type)** | This paper | N/A

**SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD (R683A, R685A, F817P, A892P, A899P, A942P, K986P, V987P)-His Recombinant Protein** | Sino Biologicals | Cat#40589-V08H4

**ACE2 Protein, Human, Recombinant (His Tag), Biotinylated** | Sino Biologicals | Cat#10108-H08H-B

**SARS-CoV-2 (2019-nCoV) Spike S1-His Recombinant Protein (HPLC-verified)** | Sino Biologicals | Cat#40591-V08H

**Lipofectamine 2000 Transfection Reagent** | Invitrogen/Thermo Fisher | Cat#11668019

**Peptide Array, SARS-Related Coronavirus 2 Spike (S) Glycoprotein** | BEI Resources | Cat#NR-52402

**HisPur Ni-NTA Resin** | Thermo Scientific | Cat#88221

**Galanthus Nivalis Lectin (GNL), Agarose bound** | Vector Laboratories | Cat#AL-1243-5

**Chemicals, peptides, and recombinant proteins**

ThermoFisher, | Cat#A14524

Sino Biologicals | Cat#40589-V08H4

**Experimental models: cell lines**

HEK293T | ATCC | ATCC® CRL-3216; RRID:CVCL_0063

DF-1 | ATCC | ATCC® CRL-12203; RRID:CVCL_0570

Vero | ATCC | ATCC® CCL-81; RRID:CVCL_0059

**Experimental Models: organisms/strains**

Mouse: BALB/c | Jackson Laboratory | Cat#000651

Monkey: Macaca mulatta | Yerkes primate breeding colony | N/A

**Oligonucleotides**

Waggoner et al., 2020 | N/A

Waggoner et al., 2020 | N/A

Waggoner et al., 2020 | N/A

Continued on next page
RESOURCE AVAILABILITY

Lead contact
Request for further information and for resources and reagents, should be directed to and will be fulfilled by the Lead Contact, Rama Rao Amara (ramara@emory.edu).

Materials availability
All unique/stable reagents generated in this study are available from the Lead Contact up on reasonable request after completion of a Materials Transfer Agreement.

Data and code availability
All data supporting the experimental findings of this study are available within the manuscript and are available from the corresponding author upon request. Data tables for expression counts for single-cell RNA-Seq for BAL are deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO accession GSE165747.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Ethics Statements
Mice and rhesus macaques were housed at the Yerkes National Primate Research Center and animal experiments were approved by the Emory University Institutional Animal Care and Use Committee (IACUC) using protocols PROTO201700014 and PROTO202000057. All animal experiments were carried out in accordance to USDA regulations and recommendations derived from the Guide for the Care and Use of Laboratory Animals.

Cells and Viruses
HEK (Human Embryonic Kidney)-293T cells, DF-1 (Chicken embryo fibroblasts), and Vero cells were obtained from ATCC. All MVA vaccines were produced in Amara’s laboratory at the Emory University. SARS-CoV-2 (icSARS-CoV-2) virus was obtained from BEI resources and grown in Suthar’s laboratory at the Emory University. mNeonGreen SARS-CoV-2 (2019-nCoV/USA_WA1/2020) virus was produced by Pei Yong Shi’s laboratory at the University of Texas. The infectious clone SARS-CoV-2 (icSARS-CoV-2) was propagated in VeroE6 cells (ATCC) and sequenced (Xie et al., 2020). The titer of MVA viruses was determined using DF-1 cells and SARS-CoV-2 viruses (icSARS-CoV-2 and 2019-nCoV/USA_WA1/2020) using VeroE6 cells. VeroE6 cells and DF-1 cells were cultured in...
complete DMEM medium consisting of 1x DMEM (Corning Cellgro), 10% Fetal bovine serum (FBS), 25 mM HEPES Buffer (Corning Cellgro), 2 mM L-glutamine, 1mM sodium pyruvate, 1x Non-essential Amino Acids, and 1x antibiotics. Viral stocks were stored at −80°C until further use.

**Animal models**

Specific-pathogen-free (SPF) 6–8-week-old female BALB/c mice (00065 strain) were obtained from Jackson Laboratories (Wilmington, MA, USA) and housed in the animal facility at the Yerkes National Primate Research Center of Emory University, Atlanta, GA. Male Indian rhesus macaques (Macaca mulatta), 3-4.5 years old, were housed in pairs in standard non-human primate cages and provided with both standard primate feed (Purina monkey chow) fresh fruit, and enrichment daily, as well free access to water. Immunizations, blood draws, and other sample collections were performed under anesthesia with ketamine (5-10 mg/kg) or telazol (3-5 mg/kg) performed by trained research and veterinary staff.

**METHOD DETAILS**

**Construction and characterization of MVA vaccines**

The MVA recombinants expressing the full-length spike (amino acids 1-1273) carrying the prefusion-stabilized mutations (MVA/S) or only S1 portion of spike (amino acids 14-780) (MVA/S1) were generated and confirmed by standard methods. SARS-CoV-2 (GenBank: MN908227.1; Wuhan strain) S ORF was codon optimized for vaccinia virus expression, synthesized using GenScript services, and cloned into pLW-73 (provided by L. Wyatt, National Institutes of Health) between the Xmal and BamH1 sites under the control of the vaccinia virus modified H5 (mH5) early late promoter and adjacent to the gene encoding enhanced GFP (green fluorescent protein) (Wyatt et al., 2004). To promote active secretion of the S1, we replaced amino acids 1-14 of the spike sequence with the signal sequence from GM-CSF (WLGQLLLLGTGACSSIS). Plaques were picked for 7 rounds to obtain GFP-negative recombinants and DNA sequenced to confirm lack of any mutations. Viral stocks were purified from lysates of infected DF-1 cells using a 36% sucrose cushion and titrated using DF-1 cells by counting pfu/ml. Absence of the wild-type MVA was confirmed by PCR using recombinant specific primers, flanking the inserts.

**Flow staining for SARS-CoV-2 Spike protein expression**

DF-1 cells were infected with MVA/S or MVA/S1 at an MOI of 1 and stained around 36hrs post-infection. MVAS-infected cells were harvested and stained with live-dead dye and anti-SARS-CoV-2 spike antibody (GTX135356, GeneTex), followed by donkey anti-rabbit IgG coupled to PE (406421, BioLegend). Cells were then fixed, permeabilized and intracellularly stained for SARS-CoV-2 RBD Ab (40592-T62, SinoBiological), followed by staining with donkey anti-Rabbit IgG PE and anti-Vaccinia virus E3L-PacBlue. For detection of human ACE2 binding to surface expressed spike on MVA/S infected DF-1 cells, were incubated with biotinylated human ACE2 protein (1:500 dilution) (10108-H08H-B, Sino Biological) followed by streptavidin-PE (BD PharMingen). Cells were then stained intracellularly for MVA as described above.

**Protein expression and purification**

RBD-His and S1 proteins were produced in Amara laboratory by transfecting HEK293 cells using plasmids pCAGGS-RBD-His and pGA8-S1, respectively. The RBD-His plasmid was obtained from BEI resources (Cat# NR-52309). The pGA8-S1 plasmid was generated by cloning human codon-optimized S1 DNA sequence from amino acids 14-780 with GM-CSF signal sequence under the control of CMV promoter with intron A. Transfections were performed according to manufacturer’s instructions (Thermo Fisher). Briefly, HEK293F cells were seeded at a density of 2x10^6 cells/ml in Expi293 expression medium and incubated in an orbital shaking incubator at 37°C and 127 rpm with 8% CO2 overnight. Next day, 2.5x10^6 cells/ml were transfected using Expifectamine™ 293 transfection reagent (Thermo Fisher, cat. no. A14524) as per manufacturer’s protocol. The cells were grown for 72h at 37°C,127 rpm, 8% CO2. The cells were harvested and collected by centrifugation at 2,000 g for 10 min at 4°C. The supernatant was filtered using a 0.22 μm sterile filter (ThermoFisher, cat.no. 290-4520) and loaded onto pre-equilibrated affinity column for protein purification. The SARS-CoV-2 RBD-His tag and S1 proteins were purified using Ni-NTA resin (ThermoFisher, cat.no. 88221) and Agarose bound Galanthus Nivalis Lectin (GNL) (Vector Labs, cat. no. AL-1243-5) respectively. Briefly, His-Pur Ni-NTA resin was washed with PBS by centrifugation at 2000 g for 10 min. The resin was resuspended with the supernatant and incubated for 2h on a shaker at RT. Polypropylene column was loaded on the supernatant-resin mixture and washed with wash Buffer (25mM Imidazole, 6.7mM NaH2PO4, H2O and 300mM NaCl in PBS) four times, after which the protein was eluted in elution buffer (235mM Imidazole, 6.7mM NaH2PO4, H2O and 300mM NaCl in PBS). S1 protein supernatants were mixed with GNL-resin overnight on rocker at 4°C. The supernatant-resin mix was loaded on to the column and washed 3 times with PBS and eluted using 1M methyl- α-D mannoopyranoside (pH7.4). Eluted proteins were dialysed against PBS using Slide-A-Lyzer Dialysis Cassette (ThermoScientific, Cat# 66030) and concentrated using either 10 kDa Amicon Centrifugal Filter Units (for RBD) or 50 kDa Amicon Centrifugal Filter Units (for S1), at 2000 g at 4°C. The concentrated protein elutes were run on a Superdex 200 Increase 10/300 GL (GE Healthcare) column on an Akta™ Pure (GE Healthcare) system and collected the peak that is matching to corresponding protein. The quantity of the proteins were estimated
by BCA Protein Assay Kit (Pierce) and quality by BN-PAGE (NuPAGE, 4%–12% Bis-Tris Protein Gels, ThermoScientific), SDS-PAGE and western blot.

**Western Blotting**

DF-1 cells were infected either with recombinant MVA/S or MVA/S1, at MOI of 1 for 36 h. Infected cells were lysed in ice-cold RIPA buffer and supernatants were collected. Lysates were kept on ice for 10 min, centrifuged, and resolved by SDS-PAGE using precast 4%–15% SDS polyacrylamide gels (BioRad). Proteins were transferred to a nitrocellulose membrane, blocked with 1% casein blocker overnight (Cat# 1610782 BioRad), and incubated for 1 h at room temperature with mouse monoclonal anti-SARS-CoV-2 spike antibody (Cat# GTX632604, GeneTex) for MVA/S, and rabbit SARS-CoV-2 RBD polyclonal antibody (Cat# 40592-T62, Sino Biological) for MVA/S1 diluted 1:2500 in blocking buffer, respectively. The membrane was washed in PBS containing Tween-20 (0.05%) and was incubated for 1 h with horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody (Southern Biotech) diluted 1:20,000. The membranes were washed, and proteins were visualized using the ECL select chemiluminescence substrate (Cat# RPN2235 GEhealthcare).

**Animal Vaccination**

BALB/c mice of 6–8-week-old female were immunized with 10^7 plaque-forming units (pfu) of MVA/S or MVA/S1 vaccine in the thigh muscle (dose split equally into each thigh) using 25 gauge needle on weeks 0 and 3. Following 2-weeks each immunizations, the blood samples were collected by facial vein puncture in BD Microtainer Tube for analyzing SARS-CoV-2 S (RBD, S1 and S)-specific serum antibody responses. At three weeks after the boost, animals were euthanized using CO2, followed by cervical dislocation. Blood, lung tissue and bronchoalveolar lavage (BAL) were collected.

10 Indian-origin adult male rhesus macaques (Macaca mulatta), 4-5 years old, were randomly allocated into two groups; one group (n = 5) received MVA-empty vector (MVA-wt) and the second group (n = 5) received MVA-expressing prefusion stabilized (with proline mutations) SARS-CoV-2 full-length spike protein (MVA/S). Animals received 1x10^8 pfu in 1 mL vaccines at week 0 and week 4 by the intramuscular (IM) route.

**SARS-CoV-2 Challenge of rhesus macaques**

All macaques were challenged with a total of 5x10^4 pfu (2.5x10^4 pfu/ml) of SARS-CoV-2 at week 8. Virus was administered as 1 mL by intratracheal (IT) and 1mL by intranasal (IN) route (0.5 mL in each nostril). All the swab samples (nasal and throat) were collected, stored immediately in the viral transport media, and processed for viral RNA extraction the same day. The animal study was conducted at Yerkes National Primate Research Center, Emory University, and was approved by the Emory IACUC.

**Binding antibody responses using ELISA**

SARS-CoV-2 S (RBD, S1 and S)–specific IgG in serum and BAL was quantified by enzyme-linked immunosorbent assay (ELISA) as described previously (Chamcha et al., 2015). Briefly, Nunc high-binding ELISA plates were coated with 2 μg/ml of recombinant SARS-CoV-2 proteins (RBD, S1 and S) proteins in Dulbecco’s phosphate-buffered saline (DPBS) and incubated overnight at 4 °C. SARS-CoV-2 RBD and S1 proteins were produced in the lab whereas, S1 and S (S1 + S2 ECD) proteins were purchased. Plates were then blocked with 5% blotting-grade milk powder and 4% whey powder in DPBS with 0.05% Tween 20 for 2h at room temperature (RT). Plates were then incubated with serially diluted serum samples (starting from 100, 3 fold, 8x) and incubated for 2h at RT followed by 6 washes. Total SARS-CoV-2 S (RBD, S1 and S)–specific mouse IgG and monkey IgG antibodies were detected using HRP-conjugated anti-mouse (1:6000) (Southern Biotech; AL, USA) and goat anti-monkey IgG secondary antibody (1:10, 000), respectively for 1 h at RT. The plates were washed and developed using TMB (2-Component Microwell Peroxidase Substrate Kit) and the reaction was stopped using 1N phosphoric acid solution. Plates were read at 450 nm wavelength within 30 min using a plate reader (Molecular Devices; San Jose, CA, USA). ELISA endpoint titers were defined as the highest reciprocal serum dilution that yielded an absorbance > 2-fold over background values.

**Live-virus neutralization**

Live-virus SARS-CoV-2 neutralization antibodies were assessed using a full-length mNeonGreen SARS-CoV-2 (2019-nCoV/USA_WA1/2020) virus, generated as previously described (Xie et al., 2020). Vaccinated mice, NHP and post-challenge sera were incubated at 56 °C for 30 min and manually diluted in duplicate in serum-free Dulbecco’s Modified Eagle Medium (DMEM) and incubated with 750-1000 focus-forming units (FFU) of infectious clone derived SARS-CoV-2-mNG virus (Xie et al., 2020) at 37 °C for 1 h. The virus/serum mixture was added to VeroE6 cell (C1008, ATCC, #CRL-1586) monolayers, seeded in 96-well blackout plates, and incubated at 37 °C for 1 h. Post incubation, the inoculum was removed and replaced with pre-warmed complete DMEM containing 0.85% methylcellulose. Plates were incubated at 37 °C for 24 h. After 24 h, the methylcellulose overlay was removed, cells were washed three times with phosphate-buffered saline (PBS), and fixed with 2% paraformaldehyde (PFA) in PBS for 30 min at room temperature. PFA is then removed and washed twice with PBS. The foci were visualized using an ELISPOT reader (CTL ImmunoSpot S6 Universal Analyzer) under a FITC channel and enumerated using Viridot (Katzelnick et al., 2018). The neutralization titers were calculated as follows: 1 - ratio of the (mean number of foci in the presence of sera: foci at the highest dilution of respective sera sample). Each specimen is tested in two independent assays performed at different times. The focus-reduction neutralization mNeonGreen...
live-virus 50% titers (FRNT-mNG50) were interpolated using a 4-parameter nonlinear regression in GraphPad Prism 8.4.3. Samples that did not neutralize at the limit of detection at 50% were plotted at 10 and were used for geometric mean calculations.

Pseudovirus neutralization assay
SARS-CoV-2 neutralization was assessed with Spike-pseudotyped virus in 293T/ACE2 cells as a function of reductions in luciferase (Luc) reporter activity. 293T/ACE2 cells were kindly provided by Drs. Mike Farzan and Huihui Mu at Scripps. Cells were maintained in DMEM containing 10% FBS and 3 μg/ml puromycin. An expression plasmid encoding codon-optimized full-length Spike of the Wuhan-1 strain (VRC7480), was provided by Drs. Barney Graham and Kizzmekia Corbett at the Vaccine Research Center, National Institutes of Health (USA). The D614G amino acid change was introduced into VRC7480 by site-directed mutagenesis using the Quik-Change Lightning Site-Directed Mutagenesis Kit from Agilent Technologies (Catalog # 210518). The mutation was confirmed by full-length Spike gene sequencing. Pseudovirions were produced in HEK293T/17 cells (ATCC cat. no. CRL-11268) by transfection using Fugene 6 (Promega Cat#E2692) and a combination of Spike plasmid, lentiviral backbone plasmid (pCMV ΔR8.2) and firefly Luc reporter gene plasmid (pHR’ CMV Luc) (Naldini et al., 1996) in a 1:17:17 ratio. Transfections were allowed to proceed for 16-20 h at 37°C. Medium was removed, monolayers rinsed with growth medium, and 15 mL of fresh growth medium added. Pseudovirus-containing culture medium was collected after an additional 2 days of incubation and was clarified of cells by low-speed centrifugation and 0.45 μm micron filtration and stored in aliquots at –80°C. TCID50 assays were performed on thawed aliquots to determine the infectious dose for neutralization assays (RLU 500-1000x background, background usually averages 50-100 RLU). For neutralization, a pre-titrated dose of virus was incubated with 8 serial 3-fold or 5-fold dilutions of serum samples or mAbs in duplicate in a total volume of 150 μl for 1 h at 37°C in 96-well flat-bottom poly-L-lysine-coated culture plates (Corning Biocoat). Cells were suspended using TrypLE express enzyme solution (Thermo Fisher Scientific) and immediately added to all wells (10,000 cells in 100 μL of growth medium per well). One set of 8 control wells received cells + virus (virus control) and another set of 8 wells received cells only (background control). After 66-72 hr of incubation, medium was removed by gentle aspiration and 30 μL of Promega 1X lysis buffer was added to all wells. After a 10-minute incubation at room temperature, 100 μl of Bright-Glo luciferase reagent was added to all wells. After 1–2 min, 110 μl of the cell lysate was transferred to a black/white plate (Perkin-Elmer). Luminescence was measured using a PerkinElmer Life Sciences, Model Victor2 luminometer. Neutralization titers are the serum dilution (ID50/ID80) or mAb concentration (IC50/IC80) at which relative luminescence units (RLUs) were reduced by 50% and 80% compared to virus control wells after subtraction of background RLU. Maximum percent inhibition (MPI) is the % neutralization at the lowest serum dilution or highest mAb concentration tested. Serum samples were heat-inactivated for 30 min at 56°C prior to assay.

Antibody isotype, IgG subclass and FcR binding of mouse sera
For relative quantification of antigen-specific antibody titers, a customized multiplexed approach was applied, as previously described (Brown et al., 2012). Therefore, magnetic microspheres with a unique fluorescent signature (Luminex) were coupled with SARS-CoV-2 antigens including spike protein (S) (provided by Eric Fischer, Dana Farber), Receptor Binding Domain (RBD), and CoV hKU1 RBD (provided by Aaron Schmidt, Ragon Institute), CoV-2 S1 and S2 (Sino Biologicals) as well as influenza as control (Immune Tech). Coupling was performed using EDC (Thermo Scientific) and Sulfo-NHS (Thermo Scientific) to covalently couple antigens to the beads. 1.2x10^6 beads per region/antigen were added to a 384-well plate (Greiner), and incubated with diluted plasma samples (1:90 for all readouts) for 16h while shaking at 900rmp at 4°C prior to assay. PE-coupled secondary antibodies for each antibody isotype or subclass (Southern Biotech) was used to detect antigen-specific antibody titer. For FcRs, biotinylated FcRs were labeled with streptavidin-PE before addition to immune complexes. Fluorescence was measured with an iQue (Intellicyt) and analyzed using Forecyt software. Data are reported as median fluorescence intensity (MFI).
ADCP, ADNP, and ADCD Assays

Antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP) and antibody-dependent complement deposition (ADCD) was measured as previously described (Ackerman et al., 2011; Fischinger et al., 2019; Karsten et al., 2019). For ADCP and ADNP, yellow-green fluorescent neutravidin beads were coupled to biotinylated SARS-CoV-2 S or RBD. For ADCD, red fluorescent neutravidin beads were coupled to biotinylated SARS-CoV-2 S or RBD. Antigen-coupled beads were then incubated with appropriately diluted plasma (ADCP 1:100, ADNP 1:50, ADCD 1:10) for 2 h at 37°C to form immune complexes. For ADCP, THP-1 s (ATCC) were added at 1.25x10^5 cells/mL and incubated for 16 h at 37°C. For ADNP, leukocytes were isolated from fresh peripheral whole blood by lysing erythrocytes using ammonium-chloride potassium lysis. Leukocytes were added to immune complexes at 2.5x10^5 cells/mL and incubated for 1 h at 37°C. Neutrophils were detected using anti-human CD66b PacBlue (Biolegend). For ADCD, lyophilized guinea pig complement (Cedarlane) was resuspended, diluted in gelatin veronal buffer with calcium and magnesium (GVB++, Boston BioProducts) and added to immune complexes. The deposition of C3 was detected using an anti-C3 FITC antibody (Mpbio).

All functional assays were acquired with an iQue (Inellicyt) and analyzed using Forecyt software. For ADCP, event were gated on singlets and fluorescent cells. For ADNP, bead-positive neutrophils were defined as CD66b positive, fluorescent cells. For both ADCP and ADNP, a phagocytic score was defined as (percentage of bead-positive cells) x (MFI of bead-positive cells) divided by 10000. For ADCD, data were reported as median fluorescence of C3 deposition (MFI).

Cell processing

For mouse studies, spleens and lungs of vaccinated and control animals were removed and placed on ice in cold RPMI 1640 (1X) with 5% FBS (Company, state, USA). 1X β-Mercaptoethanol (Invitrogen, State, USA) was added to complete medium to isolate splenocytes. Whereas lungs were cut into small pieces and incubated at 37°C in RPMI (1X) medium containing Collagenase type IV and DNase I with gentle shaking for 30 min. After incubation, cells were isolated by forcing tissue suspensions through a 70 μm cell strainer. RBCs were removed by ACK lysis buffer and live cells counted by trypan blue exclusion. For macaques, PBMC from blood collected in sodium citrate CPT tubes were isolated using standard procedures. Post SARS-CoV-2 challenge, samples were processed and stained in BSL-3 facility.

To collect BAL fluids and processing, and single-cells isolation, up to 50 mL physiological saline was delivered through trachea to the lungs of anesthetized animals using a camera enabled fiberoptic bronchoscope. The flushed saline was re-aspirated 5 times before pulling out the bronchoscope. This collection was filtered through 70 μm cell strainer and centrifuged at 2200 rpm for 5 min. Pelleted cells were suspended in 1ml R10 medium (RPMI(1X), 10% FBS) and stained as described in sections below.

For processing lymph-node, lymph-node biopsies were dissociated using 70 μm cell strainer. The cell suspension was washed twice with R-10 media.

Intracellular Cytokine Staining (ICS)

Functional responses of SARS-CoV-2 RBD, S1 and S2 specific CD8+ and CD4+ T cells in vaccinated animals were measured using peptide pools and intracellular cytokine staining (ICS) assay. Overlapping peptides (13 or 17 mers overlapping by 10 amino acids) were obtained from BEI resources (NR-52402 for spike and NR-52419 for nucleocapsid) and different pools (S1, S2, RBD and NC) were made. The S1 pool contained peptides mixed from 1-97, S2 pool contained peptides mixed from 98-181, RBD pool contained peptides 46-76 and NC pool contained 57 peptides. Each peptide was used at 1 μg/ml concentration in the stimulation reaction. Two million cells suspended in 200 μL of RPMI 1640 medium with 10% FBS were stimulated with 1 μg/ml CD28 (BD Biosciences), 1 μg/ml CD49d (BD Biosciences) co-stimulatory antibodies and different peptide pools. These stimulated cells were incubated at 37°C in 5% CO2 conditioned incubator. After 2hrs of incubation, 1 μL Golgi-plug and 1 μL Golgi-stop/ml (both from BD Biosciences) were added and incubated for 4 more hours. After total 6 h of incubation, cells were transferred to 4°C overnight and were stained the next day. Cells were washed once with FACS wash (1XPBS, 2% FBS and 0.05% sodium azide) and surface stained with Live/Dead-APC-Cy7, anti-CD3, anti-CD4 and anti-CD8, each conjugated to a different fluorochrome for 30 min at RT. The stained cells were washed once with FACS wash and permeabilized with 200 μL of cytofix/cytoperm for 30 min at 4°C. Cells were washed once with perm wash and incubated with anti-cytokine antibodies for 30 min at 4°C. Finally, the samples were washed once with perm wash and once with FACS wash, and fixed in 4% paraformaldehyde solution for 20 min before acquiring on BD LSR Fortessa flow cytometer. Data were analyzed using FlowJo software.

Histopathological examination

For visualizing iBALT structures in mouse lungs by Immunohistostereotaxy, the lung tissues were fixed in 4% PFA for 12h followed by PBS wash. Fixed lungs tissues were kept in 30% sucrose overnight followed by freezing in OCT solution. Frozen blocks were cryosectioned, fixed, and immunostained for iBALT structure. Sections were incubated overnight at 4°C with primary antibodies containing rat anti-mouse B220 (Cat#130-042-401) and hamster anti-mouse CD3 (Cat#550277). Next day, primary antibodies were washed with chilled PBS thrice followed by incubation with secondary antibodies containing anti-rat IgG-Alexa 488 (Cat#ab150157) and anti-hamster IgG-Alexa 546 (Cat#A-21111). Sections were incubated with secondary antibodies at room temperature for 1h followed by wash with chilled PBS thrice. Washed sections were mounted with antifade mounting media with DAPI. Imaging was performed at Olympus FV1000 confocal microscope using 20X objective. Number of iBALT structures were quantified per image section and plotted using GraphPad prism version 8.
For histopathologic examination in macaques, the animals were euthanized due to the study end point, and a complete necropsy was performed. For histopathologic examination, various tissue samples including lung, nasal turbinates, trachea, tonsils, hilar lymph nodes, spleen, heart, brain, gastrointestinal tract (stomach, jejunum, ileum, colon, and rectum), testes were fixed in 10% neutral-buffered formalin for 24h at room temperature, routinely processed, paraffin-embedded, sectioned at 4 μm, and stained with hematoxylin and eosin (H & E). The H & E slides from all tissues were examined by two board certified veterinary pathologists. For each animal, all the lung lobes were used for analysis and affected microscopic fields were scored semiquantitatively as Grade 0 (None); Grade 1 (Mild); Grade 2 (Moderate) and Grade 3 (Severe). Scoring was performed based on these criteria: number of lung lobes affected, type 2 pneumocyte hyperplasia, alveolar septal thickening, fibrosis, perivascular cuffing, peribronchial hyperplasia, inflammatory infiltrates, hyaline membrane formation. An average lung lobe score was calculated by combining scores from each criterion. Digital images of H&E stained slides were captured at 100 × and 200 × magnification with an Olympus BX43 microscope equipped with a digital camera (DP27, Olympus) using CellSens® Standard 2.3 digital imaging software (Olympus).

**Immunophenotyping of BAL and LN cells**

Briefly, the cells were stained with surface antibody cocktail and incubated at RT for 30 min. The stained cells were given a FACS wash and permeabilized with 1ml perm buffer (Invitrogen) for 30 min at RT. These cells were given a perm wash (Invitrogen) and stained with an intracellular antibody cocktail for 30 min at RT. Finally, the cells were washed once with perm wash and a FACS wash and fixed in 4% paraformaldehyde solution for 20 min before acquiring on BD LSR-II flow cytometer. Samples prior to challenge were acquired without 20-minute 4% paraformaldehyde fixation.

BAL innate cell surface antibody cocktail: live/dead stain-APC-cy7, anti-CD3-605, anti-CD20-605, anti-NKG2A-APC, anti-HLA-DR-PERCP, anti-cc11b-PE/Dazzle 594, anti-163-eflour-450, anti-CD123-PECy7, anti-CD11c-BV655 and anti-BDC1-1-BV711. BAL innate cell intracellular antibody: anti-Ki67-BV786. T cell phenotype surface antibody cocktail: live/dead stain-APC-cy7, anti-CD3-PERCP, anti-CD4-BV655, anti-CD8-BV711, anti-CD19-BV421, anti-CXCR5-PE and anti-CXCR3-BV605. T cell phenotype intracellular antibody: anti-Ki67-BV786. B Cell phenotype surface antibody cocktail: live/dead stain-APC-cy7, anti-CD3-607 and anti-CD20-605, B cell phenotype intracellular antibody: anti-BCL6-PE-CF594 and anti-Ki67-PECy7.

**Viral RNA extraction and quantification**

SARS-CoV-2 genomic and subgenomic RNA was quantified in naso-phyangeal (NP) swabs, throat swabs, and broncho-alveolar lavages (BAL). Swabs were placed in 1ml of Viral Transport Medium (VTM; Labscoop (VR2019-1L)). Viral RNA was extracted from NP swabs, throat swabs, and BAL on fresh specimens using the QiaAmp Viral RNA mini kit according to the manufacturer’s protocol. Quantitative PCR (qPCR) was performed on genomic viral RNA using the N2 primer and probe set designed by the CDC for their diagnostic algorithm: CoV2-N2-F: 5’-TTACAAACATTGCGCCGAAA-3’, CoV2-N2-R: 5’-GCGGAGACATCCGGAAGA-3’, and CoV2-N2-Pr: 5’-FAM-ACAAATGCCCCAGCGCTTCAG-BHQ-3’ (Waggoner et al., 2020). The primer and probe sequences for the subgenomic mRNA transcript of the E gene (Wölfel et al., 2020) are SGMRNA-E-F: 5’-CGATCTCTTGTAGATCTGTTC-3’, SGMRNA-E-R: 5’-ATTTGCAGAGTAGCAGACAA-3’, and SGMRNA-E-Pr: 5’-FAM-ACTAGCGCTAGCTTGCTTCG-3’. qPCR reactions were performed in duplicate with the Thermo-Fisher 1-Step Fast virus mastermix using the manufacturer’s cycling conditions, 200nM of each primer, and 125nM of the probe. The limit of detection in this assay was about 128 copies per ml of VTM/BAL depending on the volume of extracted RNA available for each assay. To verify sample quality the CDC RNase P p30 subunit qPCR was modified to account for rhesus macaque specific polymorphisms. The primer and probe sequences are RM-RPP30-F 5’-AGACTTGGACGTGCGAGGG-3’, RM-RPP30-R 5’-GAGCCGCTGTCCACGGT-3’, and RPP30-Pr 5’-FAM-TTCTGACCCAGGCTGC-3’. A single well from each extraction was run as described above to verify RNA integrity and sample quality via detectable and consistent cycle threshold values (Ct between 25-32).

**Single-cell RNA sequencing and analysis**

BAL samples from 5 monkeys in each group were pooled together and two technical replicate 10X captures were performed. One replicate capture failed for the control group. The libraries were run on Nova Seq 6000 lanes and the resultant bcl files were converted to count matrices using Cell Ranger v3.1 (https://support.10xgenomics.com/single-cell-gene-expression/software/downloads/latest?). Count matrices for each capture were processed using an in-house single-cell RNA-seq pipeline that uses Seurat v3.0 (Butler et al., 2018; Stuart et al., 2019). CITE-seq-Count (https://github.com/Hoohm/CITE-seq-Count) was used along with HTODemux function in Seurat to demultiplex samples. The cells expressing nFeature _RNA < 300 and > 10% mitochondrial genes, HBB, RPS or RPL genes were filtered along with doublets. One of the samples within the Vaccine group (Rcc18) was dropped due to 10-fold higher number of cells compared to other samples. Post filtration, cells from each capture were normalized using SCTransform normalization and then integrated in Seurat. After integration, Principal Component analysis was carried out. PCs 1-30 were chosen for clustering analysis, as there was very little additional variance beyond PC 30. Cell were clustered based on PC scores using the Louvain method. UMAP method (McInnes et al., 2018) was used to visualize the single cells in 2d embedding. We used Human primary cell atlas from SingleR (Aran et al., 2019) and knowledge of canonical markers to classify cells into different cell subtypes (Figures S4, Canonical, and S5, Top10Clusters). Differential gene expression between Control and Vaccine group was assessed by MAST (McDavid et al., 2017). Heatmaps, Dot plots, Violin plots and Feature plots were generated using seurat package in R. Additionally, we performed Gene set enrichment analysis using WebGestalt (Liao et al., 2019; Zhang et al., 2005).
QUANTIFICATION AND STATISTICAL ANALYSIS

The difference between any two groups at a time point was measured either using a two-tailed nonparametric Mann–Whitney rank-sum test or unpaired parametric t test depending on the distribution of the data. Comparisons between different time points within a group used paired parametric t test. P value of less than 0.05 was considered significant. The correlation analysis was performed using Spearman rank test. GraphPad Prism version 8.4.3 (471) (GraphPad Software) was used to perform data analysis and statistics.